Compound Halts Growth of Malaria Parasite
News Apr 03, 2012
The compound created in the labs of Nobel laureate Sidney Altman and co-senior author Choukri Ben Mamoun at the Yale School of Medicine penetrates red blood cells and targets molecular machinery that enables the parasite to grow within the cells, according to findings published the week of April 2 in the Proceedings of the National Academy of Sciences.
Malaria sickens more than 200 million people and kills more than a million people annually. The disease is caused by fives species of parasites of the genus Plasmodium, which is transmitted to humans by mosquitoes.
“While we primarily looked at one species of parasite, it is clear the compound also knocks out drug-resistant strains of malaria as well,” Altman said. “This compound can wipe out strains that are currently resistant to drugs such as chloroquine and pyrimethamine.”
The work is an outgrowth of the discovery by Yale immunobiology professor Alfred L. M. Bothwell of a basic peptide that the Yale team showed can penetrate cell walls and membranes. Altman and colleagues also added a piece of RNA to this peptide which then attaches to messenger RNA produced by parasites within the blood cells. The presence of this complex activates a molecular response that disables the parasite.
Altman’s lab has already shown this compound can kill dangerous strains of bacteria and is currently investigating its efficacy in combating infections in skin wounds. The current paper illustrates the compound’s effectiveness in red blood cell tissue culture. Altman stressed that more tests must be conducted to make sure the compound works in animals and people as well.
“It will be some time before this is commercially available,” Altman said.
Altman was awarded the Nobel Prize in Chemistry in 1989 along with Thomas R. Cech for their discoveries of the catalytic properties of RNA.
Other Yale authors of the study are Yoann Augagneur, Donna Wesolowski and Hyun Seop Tae.
The National Institutes of Health and Burroughs Wellcome Fund were the primary funding sources for the study.
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE
What Does the Future of Vaccines and Immunotherapy Look Like?News
Innovative biomaterials could enhance vaccines against HIV and other infectious diseases and immunotherapies for patients with cancer or dampen responses in autoimmune disorders, allergies and transplanted organ recipients. A review of these efforts was recently released.READ MORE
CMC Biologics Announces Development and Manufacturing Agreement with Harpoon TherapeuticsNews
Companies have entered into agreement for the development and manufacturing of three TriTAC molecules for the treatment of cancers.READ MORE